NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Rauwolfia serpentina root is a botanical extract derived from the Indian snakeroot plant, historically used in traditional medicine and early antihypertensive therapy. The product is presented as an oral tablet formulation under NDA review by Bausch + Lomb. Mechanism of action and specific therapeutic indications are not documented in available data.
Pre-Launch
Early-stage pre-launch positioning offers opportunity to shape commercial strategy, though market trajectory remains undefined pending regulatory and clinical clarity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch natural product offers entry-level opportunity for professionals interested in botanical/traditional medicine regulation and commercialization. With zero current job openings and undefined market positioning, career growth depends heavily on successful FDA approval and clinical validation.
Regulatory Affairs ManagerBrand Manager
Worked on RAUWOLFIA SERPENTINA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.